KALA BIO
KALA
79 hedge funds and large institutions have $30.9M invested in KALA BIO in 2021 Q4 according to their latest regulatory filings, with 17 funds opening new positions, 15 increasing their positions, 28 reducing their positions, and 35 closing their positions.
0% less ownership
Funds ownership: 0.02% → 0.02% (-0%)
20% less funds holding
Funds holding: 99 → 79 (-20)
46% less repeat investments, than reductions
Existing positions increased: 15 | Existing positions reduced: 28
51% less first-time investments, than exits
New positions opened: 17 | Existing positions closed: 35
53% less call options, than puts
Call options by funds: $69K | Put options by funds: $146K
61% less capital invested
Capital invested by funds: $79.4M → $30.9M (-$48.6M)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of America
Charlotte,
North Carolina
|
+$872K |
| 2 |
BNP Paribas Financial Markets
Paris,
France
|
+$812K |
| 3 |
PAMS
Pictet Asset Management (Switzerland)
Geneva 73,
Switzerland
|
+$464K |
| 4 |
VF
Virtu Financial
New York
|
+$237K |
| 5 |
D.E. Shaw & Co
New York
|
+$199K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
-$9.01M |
| 2 |
CC
Caxton Corporation
Princeton,
New Jersey
|
-$3.19M |
| 3 |
BlackRock
New York
|
-$984K |
| 4 |
Brown Advisory
Baltimore,
Maryland
|
-$527K |
| 5 |
ACM
ACT Capital Management
Wayne,
Pennsylvania
|
-$498K |
KALA Hedge Fund Activity: Q4 2021 in Review
79 of the 6,499 institutional investors tracked by Wall St. Rank reported a position in KALA BIO (KALA) for Q4 2021, worth a combined $30.9M — down 61% from $79.4M a quarter earlier.
Sellers outnumbered buyers: 35 funds closed out of KALA and 17 opened new positions — a net loss of 18 holders — while 28 trimmed existing stakes and 15 added.
The largest buyer was Bank of America, adding an estimated $872K. The largest seller was OrbiMed, exiting entirely with an estimated $9.01M sold.
- 79 institutional investors held KALA BIO (KALA) as of Q4 2021, down from 99 in Q3 2021.
- Funds reported $30.9M of KALA BIO stock for Q4 2021, down 61% quarter-over-quarter.
- 17 funds opened new KALA BIO positions in Q4 2021 and 35 closed out, a net change of -18 holders.
- The largest KALA BIO buyer in Q4 2021 was Bank of America, an estimated $872K added.
- The largest KALA BIO seller in Q4 2021 was OrbiMed, an estimated $9.01M sold.
Based on aggregated 13F filings for Q4 2021.